Ravi Chandran, MD
Pulmonary Disease · Tucson, AZNPI 1730133547
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (52.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.1% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $10,039, 8.2 times the $1,228 reported in 2019.
Across 212 payments — averaging $63.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Olympus Corporation Of The Americas$2K
- Insmed, Inc.$566
- GSK$504
- Genentech USA, Inc.$250
- Actelion Pharmaceuticals US, Inc.$247
- plus $1K from 24 others
Across 24 payments — averaging $3279.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$40K
- AstraZeneca$38K
- Chiesi USA, Inc.$200
What the payments were for
- Travel & lodging$3,17824%
- Food & beverage$3,18724%
- Education$7,07453%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $8,212 |
| Olympus Corporation Of The Americas | 18 | $2,213 |
| Insmed, Inc. | 38 | $566 |
| GSK | 38 | $504 |
| Genentech USA, Inc. | 11 | $250 |
| Actelion Pharmaceuticals US, Inc. | 13 | $247 |
| Electromed, Inc. | 21 | $226 |
| Boehringer Ingelheim | 7 | $181 |
| AstraZeneca | 9 | $145 |
| Philips North America LLC | 4 | $99 |
| Resmed Corp | 4 | $97 |
| Merck | 5 | $85 |
| Sanofi | 5 | $77 |
| United Therapeutics Corporation | 3 | $73 |
| Circassia Inc. | 4 | $55 |
| Zambon USA Ltd. | 1 | $54 |
| Johnson & Johnson | 3 | $47 |
| Viatris Specialty LLC | 2 | $43 |
| Mylan Specialty L.p. | 2 | $41 |
| Verona Pharma, Inc. | 1 | $34 |
| Grifols USA, LLC | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Bayer | 1 | $16 |
| Gilead | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,439 in reported general payments places this provider in the 80th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $57,647 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $23,818 |
| EliquisApixaban | 17 | $12,141 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $11,241 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $10,930 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,414 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $6,921 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,876 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 101 | $2,712 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $1,620 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 14 | $755 |
| Ipratropium Bromide | 24 | $488 |
| Fluticasone Propionate | 26 | $267 |
| Montelukast Sodium | 19 | $150 |
| Doxycycline Hyclate | 19 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $504 | $79,81897 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $145 | $37,61473 claims |
| Boehringer IngelheimSpiriva Respimat | $181 | $9,41418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Tucson
- Abhinav MittalTucson$570K
- Sachin ChaudharyTucson$90K
- Billie BixbyTucson$35K
- Todd LocherTucson$25K
- James KneplerTucson$12K
- Ubair AhmedTucson$10K
- George ParidesMesa$913K
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.